<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01965470</url>
  </required_header>
  <id_info>
    <org_study_id>CDC-CGH-6475</org_study_id>
    <nct_id>NCT01965470</nct_id>
  </id_info>
  <brief_title>Botswana Combination Prevention Project</brief_title>
  <acronym>BCPP</acronym>
  <official_title>Botswana Combination Prevention Project: -Evaluation Protocol (Protocol #1): Research Design and Impact Evaluation -Closed Clinical Cohort Protocol (Protocol #3) Implementation, Monitoring and Evaluation of Combination HIV Prevention Interventions in Rural and Peri-Urban Communities in Botswana</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Botswana Harvard Aids Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Botswana Ministry of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvard School of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tebelopele Voluntary Counseling and Testing Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centers for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The BCPP study is designed to test the hypothesis that implementing an enhanced combination
      prevention package which includes provision of ART to all participants, regardless of CD4
      count or HIV disease severity, will impact the HIV/AIDS epidemic by significantly reducing
      population-level, cumulative HIV incidence in a defined geographic area over a period of 3
      years and will be cost-effective.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 30, 2013</start_date>
  <completion_date type="Actual">July 26, 2018</completion_date>
  <primary_completion_date type="Actual">July 26, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Population-level, cumulative HIV incidence</measure>
    <time_frame>3 years</time_frame>
    <description>Population-level cumulative HIV incidence will be measured in a cohort of HIV-negative persons identified from a 20% sample of eligible households in the 30 study communities followed annually.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2. Population-level uptake of HIV testing and counseling (HTC), ART, VL Suppression, male circumcision (MC), and PMTCT services</measure>
    <time_frame>3 years</time_frame>
    <description>Population-level uptake of each intervention will be measured in an annual survey of the 20% sample of eligible households in the 30 study communities and through analysis of routine program monitoring data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost per additional infection averted</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Combination Prevention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Scale-up of HTC services during 2 annual HTC campaigns, with a target of &gt;90% of adults having documentation of their HIV-infected status or documentation of an HIV-negative test in the preceding 12 months.
Scale-up of universal ART for all HIV-infected adults, with a target of &gt;93% of HIV positive adults receiving ART.
Scale-up of retention in care and adherence interventions, with a target of ensuring that &gt;95% of HIV-infected adults are virally suppressed with HIV-1 RNA &lt;400 copies per ML..
Scale-up of linkage to MC services, with a target of ensuring &gt;60% of HIV-negative men are circumcised.
Rapid strengthening of PMTCT services, with a target of &gt;90% of women initiated on indefinite ART (Option B+) during pregnancy remaining in care and on treatment at 12 months post-delivery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enhanced Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enhanced Care Communities will receive guidance and improved technical support for quality management and data systems at all local clinics at which individuals receive HIV care and treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Combination Prevention</intervention_name>
    <arm_group_label>Combination Prevention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Enhanced Care</intervention_name>
    <arm_group_label>Enhanced Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Protocol #1 - Baseline Household Survey (BHS): Permanent or part-time study community
             resident in any of the 30 study communities; Botswana citizen or spouse of a Botswana
             citizen; able to provide informed consent if ≥18 years old, or able to provide assent
             to complement a guardian's permission, if a minor (aged 16 or 17).

          -  Protocol #3 - Expanded treatment cohort: HIV-infected persons in Combination
             Prevention communities who are not yet on ART and are able to provide informed consent
             if ≥18 years old, or able to provide assent to complement a guardian's permission, if
             a minor (aged 16 or 17).

        Exclusion Criteria:

          -  Persons who do not meet inclusion criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet S Moore, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myron Essex, DVM, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Refeletswe Lebelonyane, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Botswana Ministry of Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shenaaz El Halabi, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Botswana Ministry of Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Makhema, MBChB, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Botswana Harvard Aids Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shahin Lockman, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Tchetgen Tchetgen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Molly Pretorius Holme, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pam Bachanas, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tafireyi Marukutira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Botswana communities and Botswana Ministry of Health clinics</name>
      <address>
        <city>Multiple Locations</city>
        <state>Multiple</state>
        <country>Botswana</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Botswana</country>
  </location_countries>
  <reference>
    <citation>Moyo S, Gaseitsiwe S, Mohammed T, Pretorius Holme M, Wang R, Kotokwe KP, Boleo C, Mupfumi L, Yankinda EK, Chakalisa U, van Widenfelt E, Gaolathe T, Mmalane MO, Dryden-Peterson S, Mine M, Lebelonyane R, Bennett K, Leidner J, Wirth KE, Tchetgen Tchetgen E, Powis K, Moore J, Clarke WA, Lockman S, Makhema JM, Essex M, Novitsky V. Cross-sectional estimates revealed high HIV incidence in Botswana rural communities in the era of successful ART scale-up in 2013-2015. PLoS One. 2018 Oct 24;13(10):e0204840. doi: 10.1371/journal.pone.0204840. eCollection 2018.</citation>
    <PMID>30356287</PMID>
  </reference>
  <reference>
    <citation>Novitsky V, Gaolathe T, Mmalane M, Moyo S, Chakalisa U, Yankinda EK, Marukutira T, Holme MP, Sekoto T, Gaseitsiwe S, Musonda R, van Widenfelt E, Powis KM, Khan N, Dryden-Peterson S, Bennett K, Wirth KE, Tchetgen ET, Bachanas P, Mills LA, Lebelonyane R, El-Halabi S, Makhema J, Lockman S, Essex M. Lack of Virological Suppression Among Young HIV-Positive Adults in Botswana. J Acquir Immune Defic Syndr. 2018 Aug 15;78(5):557-565. doi: 10.1097/QAI.0000000000001715.</citation>
    <PMID>29771781</PMID>
  </reference>
  <reference>
    <citation>Moyo S, Gaseitsiwe S, Powis KM, Pretorius Holme M, Mohammed T, Zahralban-Steele M, Yankinde EK, Maphorisa C, Abrams W, Lebelonyane R, Manyake K, Sekoto T, Mmalane M, Gaolathe T, Wirth KE, Makhema J, Lockman S, Clarke W, Essex M, Novitsky V. Undisclosed antiretroviral drug use in Botswana: implication for national estimates. AIDS. 2018 Jul 17;32(11):1543-1546. doi: 10.1097/QAD.0000000000001862.</citation>
    <PMID>29762166</PMID>
  </reference>
  <reference>
    <citation>Novitsky V, Prague M, Moyo S, Gaolathe T, Mmalane M, Yankinda EK, Chakalisa U, Lebelonyane R, Khan N, Powis KM, Widenfelt E, Gaseitsiwe S, Dryden-Peterson SL, Holme MP, De Gruttola V, Bachanas P, Makhema J, Lockman S, Essex M. High HIV-1 RNA Among Newly Diagnosed People in Botswana. AIDS Res Hum Retroviruses. 2018 Mar;34(3):300-306. doi: 10.1089/AID.2017.0214. Epub 2018 Jan 17.</citation>
    <PMID>29214845</PMID>
  </reference>
  <reference>
    <citation>Moyo S, Mohammed T, Wirth KE, Prague M, Bennett K, Holme MP, Mupfumi L, Sebogodi P, Moraka NO, Boleo C, Maphorisa CN, Seraise B, Gaseitsiwe S, Musonda RM, van Widenfelt E, Powis KM, Gaolathe T, Tchetgen Tchetgen EJ, Makhema JM, Essex M, Lockman S, Novitsky V. Point-of-Care Cepheid Xpert HIV-1 Viral Load Test in Rural African Communities Is Feasible and Reliable. J Clin Microbiol. 2016 Dec;54(12):3050-3055. Epub 2016 Oct 12.</citation>
    <PMID>27733636</PMID>
  </reference>
  <reference>
    <citation>Gaolathe T, Wirth KE, Holme MP, Makhema J, Moyo S, Chakalisa U, Yankinda EK, Lei Q, Mmalane M, Novitsky V, Okui L, van Widenfelt E, Powis KM, Khan N, Bennett K, Bussmann H, Dryden-Peterson S, Lebelonyane R, El-Halabi S, Mills LA, Marukutira T, Wang R, Tchetgen EJ, DeGruttola V, Essex M, Lockman S; Botswana Combination Prevention Project study team. Botswana's progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based survey. Lancet HIV. 2016 May;3(5):e221-30. doi: 10.1016/S2352-3018(16)00037-0. Epub 2016 Mar 24.</citation>
    <PMID>27126489</PMID>
  </reference>
  <reference>
    <citation>Novitsky V, Zahralban-Steele M, McLane MF, Moyo S, van Widenfelt E, Gaseitsiwe S, Makhema J, Essex M. Correction for Novitsky et al., Long-Range HIV Genotyping Using Viral RNA and Proviral DNA for Analysis of HIV Drug Resistance and HIV Clustering. J Clin Microbiol. 2016 Apr;54(4):1175. doi: 10.1128/JCM.00190-16.</citation>
    <PMID>27016593</PMID>
  </reference>
  <reference>
    <citation>Perriat D, Balzer L, Hayes R, Lockman S, Walsh F, Ayles H, Floyd S, Havlir D, Kamya M, Lebelonyane R, Mills LA, Okello V, Petersen M, Pillay D, Sabapathy K, Wirth K, Orne-Gliemann J, Dabis F; Universal Test and Treat Trials Consortium (UT3C). Comparative assessment of five trials of universal HIV testing and treatment in sub-Saharan Africa. J Int AIDS Soc. 2018 Jan;21(1). doi: 10.1002/jia2.25048.</citation>
    <PMID>29314658</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>October 16, 2013</study_first_submitted>
  <study_first_submitted_qc>October 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2013</study_first_posted>
  <last_update_submitted>March 11, 2019</last_update_submitted>
  <last_update_submitted_qc>March 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 2, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT01965470/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

